PCSK9 and coronary artery disorder: In recent years, some new treatments have been shown to reduce both LDL-C and Lp(a) levels, such as antisense oligonucleotides and PCSK9 inhibitors, which will certainly bring more benefits to the high-risk patients with CAD.